Loading...
Please wait, while we are loading the content...
Similar Documents
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Wiernik, Peter H. Banks, Phillip L. C. Case, Delvyn C. Arlin, Zalmen A. Periman, P. O. Todd, Mary Beth Ritch, Paul S. Enck, Robert E. Weitberg, Alan B. |
| Copyright Year | 1992 |
| Abstract | The purpose of this study was to determine the relative merits of idarubicin and daunorubicin in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated adults with AML aged 15 years or more who were randomized to receive for induction therapy cytarabine 100 mg/m2/d as a continuous 7-day infusion plus either daunorubicin 45 mg/m2/d (A + D) or idarubicin 13 mg/m2/d (A + I), daily on the first three days of treatment. Postremission therapy consisted of two courses of the induction regimen at the same daily doses, with the anthracycline administered for 2 days and cytarabine for 5. The complete response (CR) rates for evaluable patients were 70% (A + I) and 59% (A + D) (P = .08). The difference in CR rates was significant in patients aged 18 to 50 years (88% for A + I, 70% for A + D, P = .035). Resistant disease was a significantly more frequent cause of induction therapy failure with A + D than with A + I. Hyperleukocytosis (white blood cell count greater than 50,000/microL) unfavorably affected the attainment of CR with A + D but not with A + I. CR duration was significantly greater after A + I. CR duration was significantly greater after A + I treatment, and the survival of all randomized patients treated with A + I was significantly better than that observed after A + D treatment (median 12.9 months v 8.7 months, respectively, P = .038). Toxicity of the two treatments was similar, although A + I patients experienced more prolonged myelosuppression during consolidation therapy, and a greater incidence of mild chemical hepatitis was observed in the A + I group. It is concluded that, at the doses and schedule used in this study, A + I is superior to A + D for induction therapy of AML in adults. |
| File Format | PDF HTM / HTML |
| DOI | 10.1182/blood.v79.2.313.bloodjournal792313 |
| Alternate Webpage(s) | http://www.bloodjournal.org/content/bloodjournal/79/2/313.full.pdf?sso-checked=true |
| PubMed reference number | 1730080 |
| Alternate Webpage(s) | https://doi.org/10.1182/blood.v79.2.313.bloodjournal792313 |
| Journal | Medline |
| Volume Number | 79 |
| Issue Number | 2 |
| Journal | Blood |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
